TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 1 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,827 | -25.4% | 1,994,122 | +28.2% | 0.03% | -11.8% |
Q2 2023 | $23,885 | -50.5% | 1,555,013 | -27.5% | 0.03% | -46.9% |
Q1 2023 | $48,237 | +43.9% | 2,144,822 | +34.6% | 0.06% | +39.1% |
Q4 2022 | $33,512 | -99.9% | 1,593,522 | +5.7% | 0.05% | -13.2% |
Q3 2022 | $37,143,000 | -7.5% | 1,507,422 | -9.0% | 0.05% | +10.4% |
Q2 2022 | $40,150,000 | +14.8% | 1,657,022 | +22.1% | 0.05% | +17.1% |
Q1 2022 | $34,978,000 | +8.4% | 1,357,322 | +30.5% | 0.04% | +2.5% |
Q4 2021 | $32,279,000 | +7.3% | 1,039,922 | -16.2% | 0.04% | +2.6% |
Q3 2021 | $30,080,000 | +20.5% | 1,240,418 | -27.5% | 0.04% | +25.8% |
Q2 2021 | $24,968,000 | -37.1% | 1,711,322 | +7.7% | 0.03% | -36.7% |
Q1 2021 | $39,670,000 | -21.8% | 1,588,722 | -14.7% | 0.05% | -10.9% |
Q4 2020 | $50,733,000 | – | 1,861,422 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |